



Exact Sciences Pipeline



Exact Sciences pipeline for early detection of cancer

 **Cologuard[®] expansion** 

 **Pancreatic cancer** 

 **Esophageal cancer** 

 **Lung cancer** 



Our Approach to Technology

Graham Lidgard, PhD
Chief Science Officer



Exact Sciences R&D Team: Prepared to meet the challenges

Assay Experience

100+ in vitro diagnostic (IVD) products from senior R&D team

Platform Experience

20+ platform technologies developed

FDA Regulatory

80+ products with 510(k), PMA, CBER

Collaboration

6+ major collaborations (EXAS and beyond)

Proven Accomplishment


Cologuard®

Exact Sciences R&D: Proven approach through a multi-marker assay

Modeling Sensitivity/Specificity for Colon Cancer (2010)


Marker	Sensitivity	Contribution	Additive Sensitivity	Specificity	Contribution to False Positives	Subtractive Specificity
Methylation	64%	64%	64%	94%	6%	94%
Hemoglobin	64%	16%	87%	98%	3%	91%
KRAS	27%	3%	90%	99%	1%	90%
Cologuard® (2014)			92%			87%

Future biomarker combinations for cancer



Cologuard[®] built on a flexible and multi-use platform

Nucleic acid extraction



Developing a pipeline with proprietary technology and strong intellectual property

Cologuard® Process and Technology

17+ issued US patents

Pipeline Patents

30+ patent applications pending in US

Worldwide Filing

45+ issued and 30+ pending applications in foreign jurisdictions

Licenses

Key licenses to additional technology

